Bruce Neal's Publications

About Bruce Neal's Publications

Executive Director, The George Institute for Global Health, Australia

  • S-16-1: RESISTANT HYPERTENISION: CLINICAL CHARACTERISTICS AND BLOOD PRESSURE CONTROL

    Journal of Hypertension Date published:

  • S-54-1: SUBSTITUTING THE WORLDS SALT SUPPLY

    Journal of Hypertension Date published:

  • Sodium Content and Labelling of Packaged Foods and Beverages in Nigeria: A Cross-Sectional Study

    Nutrients Date published:

  • Correction: Vital Signs During the COVID-19 Outbreak: A Retrospective Analysis of 19,960 Participants in Wuhan and Four Nearby Capital Cities in China

    Global Heart Date published:

  • Randomized trials fit for the 21st century. A joint opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation

    European Heart Journal Date published:

  • Socio-economic difference in purchases of ultra-processed foods in Australia: an analysis of a nationally representative household grocery purchasing panel

    International Journal of Behavioral Nutrition and Physical Activity Date published:

  • Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial

    Cardiovascular Diabetology Date published:

  • Testing the Feasibility and Dietary Impact of a “Produce Prescription” Program for Adults with Undermanaged Type 2 Diabetes and Food Insecurity in Australia

    The Journal of Nutrition Date published:

  • Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria

    Journal of the American College of Cardiology Date published:

  • Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

    The Lancet Date published:

  • Effectiveness of a Sodium Reduction Smartphone App and Reduced Sodium Salt to Lower Sodium Intake in Adults with Hypertension: Findings from the SALTS Randomised Controlled Trial (Preprint)

    JMIR mHealth and uHealth Date published:

  • Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk

    Heart Failure Clinics Date published:

  • Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

    Cardiovascular Diabetology Date published:

  • Nation-Wide Routinely Collected Health Datasets in China: A Scoping Review

    Public Health Reviews Date published:

  • The effects on clinical trial activity of direct funding and taxation policy interventions made by government: A systematic review

    PLOS ONE Date published:

  • Abstract P201: Canagliflozin, Visit-to-visit Blood Pressure Variability, And Risk Of Cardiovascular, Kidney, And Mortality Outcomes: Pooled Individual Participant Data From The CANVAS And CREDENCE Trials

    Hypertension Date published: